Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

被引:150
|
作者
Laffeber, Charlie [1 ]
de Koning, Kelly [1 ]
Kanaar, Roland [1 ]
Lebbink, Joyce H. G. [1 ,2 ]
机构
[1] Erasmus MC, Dept Mol Genet, Oncode Inst, Erasmus MC Canc Inst, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Radiat Oncol, NL-3000 CA Rotterdam, Netherlands
关键词
coronavirus; spike receptor binding domain; mutations; angiotensin converting enzyme 2 receptor; surface plasmon resonance; MUTATIONS;
D O I
10.1016/j.jmb.2021.167058
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Rapidly spreading new variants of SARS-CoV-2 carry multiple mutations in the viral spike protein which attaches to the angiotensin converting enzyme 2 (ACE2) receptor on host cells. Among these mutations are amino acid changes N501Y (lineage B.1.1.7, first identified in the UK), and the combination N501Y, E484K, K417N (B.1.351, first identified in South Africa), all located at the interface on the receptor binding domain (RBD). We experimentally establish that RBD containing the N501Y mutation results in 7-fold stronger binding to the hACE2 receptor than wild type RBD. The E484K mutation only slightly enhances the affinity for the receptor, while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds 3-fold stronger to hACE2 than wild type RBD but 2-fold weaker than N501Y. However, the recently emerging double mutant E484K/N501Y binds even stronger than N501Y. The independent evolution of lineages containing mutations with different effects on receptor binding affinity, viral transmission and immune evasion underscores the importance of global viral genome surveillance and functional characterization. (C) 2021 The Author(s). Published by Elsevier Ltd.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] New variants of SARS-CoV-2
    Canton, Rafael
    De Lucas Ramos, Pilar
    Garcia-Botella, Alejandra
    Garcia-Lledo, Alberto
    Gomez-Pavon, Javier
    Gonzalez del Castillo, Juan
    Hernandez-Sampelayo, Teresa
    Cruz Martin-Delgado, Mari
    Martin Sanchez, Francisco Javier
    Martinez-Selles, Manuel
    Molero Garcia, Jose Maria
    Moreno Guillen, Santiago
    Rodriguez-Artalejo, Fernando
    Ruiz-Galiana, Julian
    Bouza, Emilio
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2021, 34 (05) : 419 - 428
  • [32] The names of the SARS-CoV-2 variants
    不详
    PANACEA-BOLETIN DE MEDICINA Y TRADUCCION, 2021, 22 (54): : 92 - 92
  • [33] SARS-CoV-2 Variants in Pregnancy
    Asirwatham, Alison
    Hillman, Michelle
    Khan, Lyba
    Sangermano, Lisa M.
    Leung, Katherine
    Leftwich, Heidi K.
    OBSTETRICS AND GYNECOLOGY, 2024, 143 (5S): : 5S - 6S
  • [34] The SARS-CoV-2 variants of concern
    Passi, Gouri Rao
    INDIAN PEDIATRICS, 2021, 58 (05) : 498 - 498
  • [35] The Sars-CoV-2 and its variants
    Monetti, Marcello
    Pozzetto, Bruno
    Plotton, Catherine
    Gocko, Xavier
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2021, (171): : 118 - 127
  • [36] SARS-CoV-2 Variants of Concern
    Choi, Jun Yong
    Smith, Davey M.
    YONSEI MEDICAL JOURNAL, 2021, 62 (11) : 961 - 968
  • [37] Understanding variants of SARS-CoV-2
    Burki, Talha
    LANCET, 2021, 397 (10273): : 462 - 462
  • [38] Hybrid SARS-CoV-2 variants
    Rahimi, Farid
    Abadi, Amin Talebi Bezmin
    INTERNATIONAL JOURNAL OF SURGERY, 2022, 102
  • [39] Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
    Raghu, Deepa
    Hamill, Pamela
    Banaji, Arpitha
    McLaren, Amy
    Hsu, Yu-Ting
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2022, 12 (01) : 58 - 64
  • [40] Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
    Deepa Raghu
    Pamela Hamill
    Arpitha Banaji
    Amy McLaren
    Yu-Ting Hsu
    Journal of Pharmaceutical Analysis, 2022, 12 (01) : 58 - 64